Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients

被引:151
作者
De Waele, Jan J. [1 ]
Lipman, J. [2 ,3 ]
Akova, M. [4 ]
Bassetti, M. [5 ]
Dimopoulos, G. [6 ]
Kaukonen, M. [7 ,8 ]
Koulenti, D. [2 ]
Martin, C. [9 ]
Montravers, P. [10 ]
Rello, J. [11 ]
Rhodes, A. [12 ,13 ]
Udy, A. A. [2 ,14 ]
Starr, T. [2 ]
Wallis, S. C. [2 ]
Roberts, J. A. [2 ,3 ]
机构
[1] Ghent Univ Hosp, Dept Crit Care Med, B-9000 Ghent, Belgium
[2] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[4] Hacettepe Univ Hosp, Ankara, Turkey
[5] Azienda Osped Univ Santa Maria della Misericordia, Udine, Italy
[6] Univ Athens, Sch Med, Attikon Univ Hosp, GR-11527 Athens, Greece
[7] Helsinki Univ Hosp, Helsinki, Finland
[8] Monash Univ, Dept Epidemiol & Prevent Med, Australian & New Zealand Intens Care Res Ctr ANZI, Melbourne, Vic 3004, Australia
[9] Hosp Nord, Marseille, France
[10] Ctr Hosp Univ Bichat Claude Bernard, Paris, France
[11] Vall dHebron Inst Res, CIBERES, Barcelona, Spain
[12] St Georges Healthcare NHS Trust, London, England
[13] St Georges Univ London, London, England
[14] Alfred Hosp, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
beta-Lactam antibiotics; Pharmacokinetics; Pharmacodynamics; Critical care; AUGMENTED RENAL CLEARANCE; INTENSIVE-CARE-UNIT; PLASMA CREATININE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-IMPLICATIONS; CONTINUOUS-INFUSION; SEVERE SEPSIS; PHARMACOKINETICS; INFECTIONS; PIPERACILLIN;
D O I
10.1007/s00134-014-3403-8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Risk factors for beta-lactam antibiotic underdosing in critically ill patients have not been described in large-scale studies. The objective of this study was to describe pharmacokinetic/pharmacodynamic (PK/PD) target non-attainment envisioning empirical dosing in critically ill patients and considering a worst-case scenario as well as to identify patient characteristics that are associated with target non-attainment. This analysis uses data from the DALI study, a prospective, multi-centre pharmacokinetic point-prevalence study. For this analysis, we assumed that these were the concentrations that would be reached during empirical dosing, and calculated target attainment using a hypothetical target minimum inhibitory concentration (MIC), namely the susceptibility breakpoint of the least susceptible organism for which that antibiotic is commonly used. PK/PD targets were free drug concentration maintained above the MIC of the suspected pathogen for at least 50 % and 100 % of the dosing interval respectively (50 % and 100 % f T (> MIC)). Multivariable analysis was performed to identify factors associated with inadequate antibiotic exposure. A total of 343 critically ill patients receiving eight different beta-lactam antibiotics were included. The median (interquartile range) age was 60 (47-73) years, APACHE II score was 18 (13-24). In the hypothetical situation of empirical dosing, antibiotic concentrations remained below the MIC during 50 % and 100 % of the dosing interval in 66 (19.2 %) and 142 (41.4 %) patients respectively. The use of intermittent infusion was significantly associated with increased risk of non-attainment for both targets; creatinine clearance was independently associated with not reaching the 100 % f T (> MIC) target. This study found that-in empirical dosing and considering a worst-case scenario-19 % and 41 % of the patients would not achieve antibiotic concentrations above the MIC during 50 % and 100 % of the dosing interval. The use of intermittent infusion (compared to extended and continuous infusion) was the main determinant of non-attainment for both targets; increasing creatinine clearance was also associated with not attaining concentrations above the MIC for the whole dosing interval. In the light of this study from 68 ICUs across ten countries, we believe current empiric dosing recommendations for ICU patients are inadequate to effectively cover a broad range of susceptible organisms and need to be reconsidered.
引用
收藏
页码:1340 / 1351
页数:12
相关论文
共 39 条
[1]   Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review [J].
Adnan, Syamhanin ;
Paterson, David L. ;
Lipman, Jeffrey ;
Kumar, Suresh ;
Li, Janice ;
Rudd, Michael ;
Roberts, Jason A. .
SURGICAL INFECTIONS, 2012, 13 (01) :9-17
[2]   Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues [J].
Antonelli, Massimo ;
Bonten, Marc ;
Cecconi, Maurizio ;
Chastre, Jean ;
Citerio, Giuseppe ;
Conti, Giorgio ;
Curtis, J. Randall ;
Hedenstierna, Goran ;
Joannidis, Michael ;
Macrae, Duncan ;
Maggiore, Salvatore M. ;
Mancebo, Jordi ;
Mebazaa, Alexandre ;
Preiser, Jean-Charles ;
Rocco, Patricia ;
Timsit, Jean-Francois ;
Wernerman, Jan ;
Zhang, Haibo .
INTENSIVE CARE MEDICINE, 2013, 39 (03) :345-364
[3]   Daily serum piperacillin monitoring is advisable in critically ill patients [J].
Blondiaux, Nicolas ;
Wallet, Frederic ;
Favory, Raphael ;
Onimus, Thierry ;
Nseir, Saad ;
Courcol, Rene J. ;
Durocher, Alain ;
Roussel-Delvallez, Micheline .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (05) :500-503
[4]   Identifying patients at risk for augmented renal clearance in the ICU - limitations and challenges [J].
Carlier, Mieke ;
De Waele, Jan J. .
CRITICAL CARE, 2013, 17 (02)
[5]   Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients [J].
Carlier, Mieke ;
Noe, Michael ;
De Waele, Jan J. ;
Stove, Veronique ;
Verstraete, Alain G. ;
Lipman, Jeffrey ;
Roberts, Jason A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (11) :2600-2608
[6]   Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? [J].
Carlier, Mieke ;
Carrette, Sofie ;
Roberts, Jason A. ;
Stove, Veronique ;
Verstraete, Alain ;
Hoste, Eric ;
Depuydt, Pieter ;
Decruyenaere, Johan ;
Lipman, Jeffrey ;
Wallis, Steven C. ;
De Waele, Jan J. .
CRITICAL CARE, 2013, 17 (03)
[7]   Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis [J].
Connor, Michael J., Jr. ;
Salem, Charbel ;
Bauer, Seth R. ;
Hofmann, Christina L. ;
Groszek, Joseph ;
Butler, Robert ;
Rehm, Susan J. ;
Fissell, William H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (02) :557-560
[8]   Optimization of meropenem dosage in the critically ill population based on renal function [J].
Crandon, Jared L. ;
Ariano, Robert E. ;
Zelenitsky, Sheryl A. ;
Nicasio, Anthony M. ;
Kuti, Joseph L. ;
Nicolau, David P. .
INTENSIVE CARE MEDICINE, 2011, 37 (04) :632-638
[9]   Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial [J].
De Waele, Jan J. ;
Carrette, S. ;
Carlier, M. ;
Stove, V. ;
Boelens, J. ;
Claeys, G. ;
Leroux-Roels, I. ;
Hoste, E. ;
Depuydt, P. ;
Decruyenaere, J. ;
Verstraete, A. G. .
INTENSIVE CARE MEDICINE, 2014, 40 (03) :380-387
[10]   Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial [J].
Dulhunty, Joel M. ;
Roberts, Jason A. ;
Davis, Joshua S. ;
Webb, Steven A. R. ;
Bellomo, Rinaldo ;
Gomersall, Charles ;
Shirwadkar, Charudatt ;
Eastwood, Glenn M. ;
Myburgh, John ;
Paterson, David L. ;
Lipman, Jeffrey .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (02) :236-244